Interaction of Na2B12H11SH with liposomes:: Influence on zeta potential and particle size

被引：18

作者：

Awad, D ^{[1
]}

Tabod, I

Lutz, S

Wessolowski, H

Gabel, D

机构：

[1] Univ Bremen, Dept Chem, D-28334 Bremen, Germany

[2] Univ Bremen, Inst Environm Proc Engn, D-28334 Bremen, Germany

来源：

JOURNAL OF ORGANOMETALLIC CHEMISTRY | 2005年 / 690卷 / 11期

关键词：

BSH; liposomes; liposome size; zeta potential;

D O I：

10.1016/j.jorganchem.2005.01.013

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

The interaction of Na2B12H11SH (BSH) with liposomes has been studied. BSH is a compound used clinically in boron neutron capture therapy of glioblastoma, and is known to enter tumor cells. Liposomes were used as a model for studying the interaction of BSH with cell membranes. BSH led to changes in the zeta potential of liposomes consisting of DODAB (dioctadecyldimethylammonium bromide) alone or with DOPC (dioleylphosphatidylcholine) or DOPE (dioleylphosphatidylethanolamine). It also led to changes of the size of DODAB liposomes, with a maximum size at small zeta potentials. A firm binding of BSH with the head groups of the lipid must be assumed. (c) 2005 Elsevier B.V. All rights reserved.

引用

页码：2732 / 2735

页数：4

共 50 条

[21] Subcellular biodistribution of sodium borocaptate (BSH:: Na2B12H11SH) in a rat glioma model in boron neutron capture therapy
Kageji, T
Nagahiro, S
Otersen, B
Gabel, D
Nakaichi, M
Nakagawa, Y
JOURNAL OF NEURO-ONCOLOGY, 2002, 59 (02) : 135 - 142
[22] HIGH-RESOLUTION B-10 AND B-11 NUCLEAR MAGNETIC-RESONANCE (NMR) SPECTROSCOPY OF NA2B12H11SH IMPURITIES AND METABOLITES
SAMSEL, EG
MILLER, DL
STRAHLENTHERAPIE UND ONKOLOGIE, 1989, 165 (2-3): : 140 - 141
[23] QUANTITATIVE IMAGING OF A RADIOTHERAPEUTIC DRUG, NA2B12H11SH, AT SUBCELLULAR RESOLUTION IN TISSUE-CULTURES USING ION MICROSCOPY
ZHA, XH
AUSSERER, WA
MORRISON, GH
CANCER RESEARCH, 1992, 52 (19) : 5219 - 5222
[24] Na2B12H11SH (BSH) in combination with systemic hyaluronidase: A promising concept for boron neutron capture therapy for glioblastoma - Comment
Sweet, WH
NEUROSURGERY, 1996, 39 (02) : 325 - 326
[25] The compound factor of Na2B12H11SH and the relative biological effectiveness of recoil protons for neurological damage in boron neutron capture therapy
Gabel, D
Philipp, KHI
Huiskamp, R
CANCER NEUTRON CAPTURE THERAPY, 1996, : 815 - 821
[26] Binding and distribution of Na2B12H11SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy
Otersen, B
Haritz, D
Grochulla, F
Bergmann, M
Sierralta, W
Gabel, D
JOURNAL OF NEURO-ONCOLOGY, 1997, 33 (1-2) : 131 - 139
[27] Binding and distribution of Na2B12H11SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy
Birte Otersen
Dietrich Haritz
Frank Grochulla
Markus Bergmann
Walter Sierralta
Detlef Gabel
Journal of Neuro-Oncology, 1997, 33 : 131 - 139
[28] Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture
Gabel, D
Preusse, D
Haritz, D
Grochulla, F
Haselsberger, K
Fankhauser, H
Ceberg, C
Peters, HD
Klotz, U
ACTA NEUROCHIRURGICA, 1997, 139 (07) : 606 - 612
[29] Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture
D. Gabel
D. Preusse
D. Haritz
F. Grochulla
K. Haselsberger
H. Fankhauser
C. Ceberg
H. -D. Peters
U. Klotz
Acta Neurochirurgica, 1997, 139 : 606 - 612
[30] DISTRIBUTION OF B-10 AFTER INFUSION OF (NA2B12H11SH)-B-10 INTO A PATIENT WITH MALIGNANT ASTROCYTOMA - IMPLICATIONS FOR BORON NEUTRON-CAPTURE THERAPY
FINKEL, GC
POLETTI, CE
FAIRCHILD, RG
SLATKIN, DN
SWEET, WH
NEUROSURGERY, 1989, 24 (01) : 6 - 11

← 1 2 3 4 5 →